Skip to main content
ArticleOPEN ACCESS

Reply: KRAS status analysis and anti-EGFR therapies: Is comprehensiveness a biologist's fancy or a clinical necessity

British Journal of Cancer
DOI: 10.1038/sj.bjc.6605583
0Citations
Citations of this article
3Readers
Mendeley users who have this article in their library.

References Powered by Scopus

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

Journal of Clinical Oncology
1506Citations
N/AReaders
Get full text

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer

British Journal of Cancer
515Citations
N/AReaders
Get full text

Recurrent KRAS codon 146 mutations in human colorectal cancer

Cancer Biology and Therapy
206Citations
N/AReaders
Get full text
View more at Scopus

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Cremolini, C., Ruzzo, A., Graziano, F., Falcone, A., & Loupakis, F. (2010, March). Reply: KRAS status analysis and anti-EGFR therapies: Is comprehensiveness a biologist’s fancy or a clinical necessity. British Journal of Cancer. https://doi.org/10.1038/sj.bjc.6605583

Readers' Seniority

Tooltip

Professor / Associate Prof. 1

50%

Researcher 1

50%

Readers' Discipline

Tooltip

Biochemistry, Genetics and Molecular Bi... 3

100%

Save time finding and organizing research with Mendeley

Sign up for free